Drugs / CMP-CPS-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06247670 | Feb 2024 → Dec 2027 expected | ornithine carbamoyltransferase deficiency | CAMP4 Therapeutics Corporation | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMP-CPS-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06247670 ↗ |
| Modality | Antisense oligonucleotide | “antisense oligonucleotide solution” NCT06247670 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06247670 ↗ |